{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-040825","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.058386+00:00","generated_at":"2026-06-29T22:19:10.671440+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia cuts FY2021 NUPLAZID revenue guidance to $480-515M; FDA reiterates need for additional DRP studies","bullets":["2Q21 net sales $115.2M (+5% YoY); net loss $43.9M ($0.27/share) vs $42.1M loss in 2Q20.","FY2021 revenue guidance reduced to $480-515M from $510-550M due to pandemic and higher gross-to-net (~20%).","FDA Type A meeting on pimavanserin for DRP: FDA insists on additional studies per subgroup but open to further discussion.","GAAP R&D guidance lowered to $250-270M (prior $280-300M); SG&A guidance unchanged at $385-415M.","Phase 3 LAVENDER (trofinetide for Rett syndrome) top-line expected Q4 2021; Phase 2 ACP-044 pain results also Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-040825","json":"https://secwatch.observer/filing/0001564590-21-040825.json","markdown":"https://secwatch.observer/filing/0001564590-21-040825.md","text":"https://secwatch.observer/filing/0001564590-21-040825.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000156459021040825/0001564590-21-040825-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000156459021040825/acad-8k_20210804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:19:10.671440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}